CM
EUCR

Cohanzick Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Cohanzick Management’s Portfolio EUCR Stock Details EUCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,649
Closed -$26K – 361
2022
Q2 		$26K Buy
2,649
+99
+4% +$978 0.01% 299
2022
Q1 		$25K Buy
2,550
+400
+19% +$3.93K 0.01% 358
2021
Q4 		$21K Buy
+2,150
New +$21.1K ﹤0.01% 344

Other funds holding EUCR

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Cohanzick Management's EUCR Position: Q3 2022 in Review

Cohanzick Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q3 2022, closing a stake of 2,649 shares — an estimated $26K sold.

Cohanzick Management first reported a position in EUCR in Q4 2021 and held it in 3 quarters. The position peaked at $26K in Q2 2022. 38 funds tracked by Wall St. Rank hold EUCR as of Q3 2022.

  • Cohanzick Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Cohanzick Management sold 2,649 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q3 2022, an estimated $26K.
  • Cohanzick Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2021 and held it in 3 quarters.
  • Cohanzick Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $26K in Q2 2022.
  • 38 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q3 2022.

Based on Cohanzick Management's 13F filing for Q3 2022, filed 10 Nov 2022.